Scalper1 News
A strong run by IBD’s Medical-Ethical Drugs industry group peaked on Feb. 26, six days before the Nasdaq composite did. Since then, the leading group is showing its largest correction since a two-month 12.5% drop in September to November 2012. The group has fallen as much as 13.2% from its recent high. That’s bearable for most growth investors who hold a large profit cushion in the portfolio. However, recent action by top-rated stocks has been Scalper1 News
Scalper1 News